Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), reiterating an Outperform rating and price target …
Sarepta Therapeutics Inc (NASDAQ:SRPT) granted equity awards on January 31, 2017, that were previously approved by the Compensation Committee of its Board of …
In a research report published Tuesday, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), with a …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced it has entered a research and option agreement with Nationwide Children’s Hospital on their microdystrophin gene therapy program. …
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that the European Medicines Agency (EMA) validated the previously submitted Marketing Authorization application (MAA) for eteplirsen to treat …
Cowen analyst Ritu Baral is chiming in with her two cents on Sarepta Therapeutics Inc (NASDAQ:SRPT) as to what the early days of …
Valeant Pharmaceuticals Intl Inc Wells Fargo analyst David Maris weighs in on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), as the drug maker focuses …
Sarepta Therapeutics Inc (NASDAQ:SRPT) granted equity awards on November 30, 2016, that were previously approved by the Compensation Committee of its Board of …
Sarepta Therapeutics Inc (NASDAQ:SRPT) reported financial results for the three and nine months ended September 30, 2016. “We are thrilled that the first patient …
Cowen top analyst Ritu Baral shares insight on Sarepta Therapeutics Inc (NASDAQ:SRPT) after speaking with three key opinion leaders (KOLs) regarding the recent approval …
